Literature DB >> 2457595

Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph.

M Binoux1, P Hossenlopp.   

Abstract

The extent to which the association between insulin-like growth factors (IGFs) and their specific binding proteins (BPs) prevents their crossing the capillary barrier was studied by comparing their distribution in serum with that in samples of lymph collected from the lower leg of five subjects undergoing radiographical investigation of the lymphatic system. The IGF concentrations in lymph were 10-30% of the corresponding serum levels, and in each subject the ratios of IGF-I and IGF-II in the lymph to those in the serum were similar. Western blot analysis of the BPs revealed that the five molecular forms identified in serum also were present in lymph, but in significantly smaller quantities. The 41.5K and 38.5K forms, which constitute the binding units of the large complex (approximately 150K) of serum and are also capable of binding IGFs in monomeric form, were present in smaller amounts than the 34K, 30K and 24K forms, which belong specifically to the small complex (approximately 40K) of serum. The BPs extracted from lymph were similar to those of the small complex, with a preferential affinity for IGF-II and only half of the affinity for IGF-I of the BPs extracted from serum. With neutral pH gel filtration of lymph, more than 90% of IGFs and binding activity eluted with the material in the area of the 40K zone. These data indicate that the 150K IGF-BP complexes do not cross the capillary barrier, whereas the 40K complexes do. The function of the former may be to provide a reservoir and buffering action of the IGFs, whereas the latter may be involved in the transport of the IGFs to their target cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457595     DOI: 10.1210/jcem-67-3-509

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  The role of circulating IGF-I: lessons from human and animal models.

Authors:  Shoshana Yakar; Yiping Wu; Jennifer Setser; Clifford J Rosen
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

2.  Insulin-like growth factor (IGF) binding proteins and their mRNAs in connective tissues of fasted guinea-pigs.

Authors:  A Gosiewska; B Peterkofsky
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

Review 3.  Somatomedin-binding proteins: what role do they play in the growth process?

Authors:  S Cianfarani; J M Holly
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

Review 4.  Growth factors, apoptosis, and survival of mammary epithelial cells.

Authors:  E C Rosfjord; R B Dickson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

5.  Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; C Schmid; H P Guler; M Waldvogel; C Hauri; E Futo; P Hossenlopp; M Binoux; E R Froesch
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Insulin-like growth factor binding protein-3 protease activity in the urine of children with chronic renal failure.

Authors:  D Y Lee; P Cohen; A M Krensky; R G Rosenfeld; P D Yorgin
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

8.  Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.

Authors:  M A Hussain; O Schmitz; A Mengel; Y Glatz; J S Christiansen; J Zapf; E R Froesch
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?

Authors:  J Zapf; E Futo; M Peter; E R Froesch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

10.  Modulation of brain insulin-like growth factor I (IGF-I) binding sites and hypothalamic GHRH and somatostatin levels by exogenous growth hormone and IGF-I in juvenile rats.

Authors:  Rina Eshet; Irit Gil-Ad; Olga Apelboym; Yael Segev; Moshe Phillip; Haim Werner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.